AbbVie gets crucial US approval for psoriasis drug SkyriziWith one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Share XAbbVie gets crucial US approval for psoriasis drug Skyrizihttps://pharmaphorum.com/news/abbvie-gets-crucial-us-approval-for-psoriasis-drug-skyrizi/
AbbVie’s psoriasis drug Skyrizi approved in JapanAbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this Share XAbbVie’s psoriasis drug Skyrizi approved in Japanhttps://pharmaphorum.com/news/abbvies-psoriasis-drug-skyrizi-approved-in-japan/
Question marks over AbbVie/Roche’s venetoclax after safety scareAbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a Share XQuestion marks over AbbVie/Roche’s venetoclax after safety scarehttps://pharmaphorum.com/news/question-marks-over-abbvie-roches-venetoclax-after-aml-safety-scare/
Takeda’s Entyvio outperforms AbbVie’s Humira in GI trialTakeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – Share XTakeda’s Entyvio outperforms AbbVie’s Humira in GI trialhttps://pharmaphorum.com/news/takedas-entyvio-outperforms-abbvies-humira-in-gi-trial/
AbbVie/Roche seek first-line CLL use for Venclexta comboAbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new Share XAbbVie/Roche seek first-line CLL use for Venclexta combohttps://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/
Q4 results roundup 2019With the full year results season drawing to a close, Richard Staines asks who the winners were and Share XQ4 results roundup 2019https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/
Pharma CEOs grilled by US Senators over drug pricesPharma bosses faced a grilling from the US Senate’s Finance Committee over the high price of branded prescription Share XPharma CEOs grilled by US Senators over drug priceshttps://pharmaphorum.com/news/pharma-ceos-grilled-by-us-senators-over-drug-prices/
AbbVie upscales Voyager alliance with new target, more cashAbbVie has extended its collaboration with gene therapy specialist Voyager Therapeutics, adding a new programme in Parkinson’s disease Share XAbbVie upscales Voyager alliance with new target, more cashhttps://pharmaphorum.com/news/abbvie-upscales-voyager-alliance-with-new-target-more-cash/
Market access roundup: UK HTA shakeups as Brexit fears deepenWith a Brexit deal still out of sight, there have been intensified warnings in the UK about potential Share XMarket access roundup: UK HTA shakeups as Brexit fears deepenhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-uk-hta-shakeups-as-brexit-fears-deepen/
